S. Mas

2 papers in the library · publishing 2019-2020

Papers

The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model.

Journal of Psychiatric Research April 26, 2020 A. Martínez-Pinteño, Susana García-Cerro, S. Mas et al.

A positive allosteric modulator of the metabotropic glutamate receptor 2, JNJ-46356479, partially reversed spatial working memory deficits and social motivation and memory impairments in a mouse model of schizophrenia induced by postnatal ketamine. The ketamine-treated mice also showed reduced parvalbumin-positive interneurons in the medial prefrontal cortex and dentate gyrus, along with increased c-Fos expression in the hippocampus; JNJ treatment normalized these neural markers. The results suggest that targeting mGluR2 could help improve cognitive and negative symptoms related to schizophrenia.

DOI: 10.1016/j.jpsychires.2020.04.005 Medicine

Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.

European Neuropsychopharmacology June 1, 2019 M. Bioque, S. Mas, M. Costanzo et al.

A specific genetic variation in the endocannabinoid system interacts with cannabis use to sharply increase the risk of a first episode of psychosis. Carrying two copies of the T allele of the FAAH rs2295633 gene variant, combined with cannabis use, made the probability of a first psychotic episode ten times higher compared to cannabis users without that genotype. No such increased risk appeared in non-users. The study also found that carriers of this genotype who used cannabis were more often treated with high-potency antipsychotics. The findings are preliminary and need replication.

DOI: 10.1016/j.euroneuro.2019.04.005 Medicine Psychology